2019 Annual Meeting | C198 - Integrating Sleep Medicine Concepts into Your Child Neurology Practice

Date Wednesday 05/08/19

Time 03:30 PM - 05:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Suresh Kotagal, MD, FAAN

Topic(s) Child Neurology and Developmental Neurology, Sleep

Learning Objectives The attendee will be aware of new developments in the diagnosis and management of childhood narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia; understand the pharmacotherapy of pediatric sleep problems (what, how much, and when?); appreciate the impact of sleep disruption on headache syndromes and how to address it; and understand the significance of findings displayed on nocturnal polysomnography and the multiple sleep latency test reports.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM EDT	Introduction	Introduction Suresh Kotagal, MD, FAAN
03:35 PM - 04:00 PM EDT	Speaker	Update on Pediatric Narcolepsy and Other Hypersomnia Disorders Kiran P. Maski, MD
04:00 PM - 04:30 PM EDT	Speaker	Sleep Pharmmacology: What, When, and How Much? Madeleine M. Grigg-Damberger, MD
04:30 PM - 05:00 PM EDT	Speaker	Relationship Between Headache and Sleep Problems Sanjeev V. Kothare, MD, FAAN
05:00 PM - 05:30 PM EDT	Speaker	Interesting Cases Suresh Kotagal, MD, FAAN

Faculty Disclosures
Suresh Kotagal, MD, FAAN	No disclosure on file
Kiran P. Maski, MD	An immediate family member of Dr. Maski has received personal compensation for serving as an employee of Sanofi Genzyme. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony Biosciences. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alkermes. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KemPharm. Dr. Maski has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. Dr. Maski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Hayes Legal Services. An immediate family member of Dr. Maski has stock in Sanofi Genzyme. The institution of Dr. Maski has received research support from Jazz Pharmaceuticals. The institution of Dr. Maski has received research support from NIH 5K23NS104267-2. The institution of Dr. Maski has received research support from Coverys. Dr. Maski has received publishing royalties from a publication relating to health care.
Sanjeev V. Kothare, MD, FAAN	Dr. Kothare has nothing to disclose.
Madeleine M. Grigg-Damberger, MD	Dr. Grigg-Damberger has received personal compensation for serving as an employee of Oxford University Press. Dr. Grigg-Damberger has received personal compensation for serving as an employee of Up-to-date. Dr. Grigg-Damberger has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Sleep Medicine. Dr. Grigg-Damberger has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��